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Abstract Stimulation of human platelets with thrombin caused
a 42% inhibition of the ADP-ribosyl cyclase activity of
membrane CD38. This effect was mediated by the activation of
the platelet thrombin receptor rather than by proteolysis of
CD38, and was not due to a different distribution of the
synthesised nucleotide or to a reduced accessibility of CD38 to
the substrate. The inhibitory effect of thrombin required actin
polymerisation and was not observed when interaction of CD38
with the cytoskeleton was prevented by cytochalasin D. Finally,
we analysed whether cADPR could play a role as a Ca2+-
mobilising agent in human platelets. Using saponin-permeabi-
lised cells, we found that unlike IP3, cADPR did not induce any
release of Ca2+ from intracellular stores. These results indicate
that the enzymatic activity of membrane CD38 can be modulated
by platelet activation, and that the function of this glycoprotein is
probably not related to Ca2+ mobilisation.
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1. Introduction
CD38 is a type II transmembrane glycoprotein expressed in
a variety of cells and displaying several functional properties
[1]. This molecule is an adhesion receptor able to support the
interaction of lymphocytes with endothelial cells and to bind
to hyaluronate [2,3]. Moreover, CD38 represents a cell-acti-
vating receptor that, upon ligation by selected monoclonal
antibodies, triggers speci¢c responses including proliferation
and cytokine production [4,5]. Finally, the extracellular do-
main of CD38 is a bifunctional enzyme that catalyses the
synthesis of cADPR from NAD and the hydrolysis of
cADPR to ADPR [6]. Thus, CD38 is involved in the transient
formation of cADPR, which represents a second messenger
able to stimulate the release of Ca2 from ryanodine-sensitive,
but IP3-insensitive intracellular stores [7].
During the last years, an increasing amount of information
has been produced on the e¡ect of CD38 ligation on cell
activation. In contrast, very little is known on the e¡ects of
cell activation on the biochemical properties and enzymatic
activities of CD38. An increased ADP-ribosyl cyclase activity
of CD38 has been reported in HL60 cells treated with retinoic
acid, but this e¡ect was due to the induction of CD38 mRNA
and expression of new molecules on the cell surface [8]. Evi-
dence for post-translational modi¢cations of soluble and
membrane-bound CD38, including ADP-ribosylation and oli-
gomerisation, has also been described and implications for the
enzymatic activities have been suggested [9^11]. In sea urchin
eggs, the synthesis of cADPR by a soluble ADP-ribosyl cy-
clase, and the consequent Ca2 mobilisation, was stimulated
by nitric oxide, through the activation of a guanylate cyclase
and the formation of cGMP [12,13]. However, such a regu-
lation in mammalian cells has not been reported. Recently, a
modulation of the ADP-ribosyl cyclase activity of membrane
CD38 in response to the activation of muscarinic acetylcho-
line receptors has been described [14]. In particular, m1 and
m3 subtypes of acetylcholine receptors were able to stimulate
the ADP-ribosyl cyclase activity of CD38 through the action
of a cholera toxin-sensitive G-protein, while m2 and m4 re-
ceptor subtypes caused a pertussis toxin-sensitive inhibition of
the ADP-ribosyl cyclase activity of CD38 [14].
Human platelets express enzymatically active CD38 on the
plasma membrane [15], and we have recently shown that this
glycoprotein speci¢cally interacts with the intracellular cyto-
skeleton upon cell stimulation with thrombin [16]. One of the
earliest events in platelet activation is the Ca2 mobilisation
from intracellular stores, which is mediated by IP3 formation,
but could also involve other messengers such as cADPR [17].
Therefore, in this work, we investigated the modulation of the
ADP-ribosyl cyclase activity of CD38 in intact platelets stimu-
lated with physiological agonists. Surprisingly, we found that
thrombin caused a strong inhibition of the ADP-ribosyl cy-
clase activity in intact cells, which was mediated by the inter-
action of CD38 with the cytoskeleton. Moreover, we also
observed that cADPR did not actually function as a Ca2-
mobilising agent in these cells.
2. Materials and methods
2.1. Materials
Nicotinamide guanine dinucleotide (NGD), cyclic ADP-ribose,
cytochalasin D, U46619, leupeptin, RGDS peptide, aprotinin, IP3,
and all the platelet agonists used were purchased from Sigma. The
thrombin receptor activating peptide (TRAP) and FLUO-3 were from
Calbiochem. Microcon 3 ¢lters were from Amicon. Triton X-100 was
from ICN. All other reagents were of analytical grade.
2.2. Platelet preparation and analysis of the ADP-ribosyl cyclase
activity
Human platelets were isolated by gel ¢ltration on a Sepharose 2B-
CL column, in HEPES bu¡er (10 mM HEPES, 137 mM NaCl,
2.9 mM KCl, 12 mM NaHCO3, pH 7.4) as previously described
[15]. Samples of gel-¢ltered platelets (0.5 ml) were prewarmed at
37‡C for 5 min and then treated with bu¡er or with 10 nM thrombin,
10 WM TRAP, 10 Wg/ml collagen or 10 WM U46619. In some experi-
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ments, platelet samples were incubated with 10 WM cytochalasin D for
2 min before the addition of the agonists. Two minutes after the
addition of the agonists, 100 WM NGD was added to the samples
to measure the ADP-ribosyl cyclase activity [18]. The concentrations
of the nucleotides were evaluated in 100 Wl aliquots immediately after
the addition of the substrate, and after incubation at 37‡C for 60 min.
Typically, samples were centrifuged at 13 000Ug for 3 min, and the
supernatants were ultra¢ltered on Microcon 3 membrane (cut-o¡
3000 Da). Nucleotides in the supernatants were separated and quan-
ti¢ed by reverse phase HPLC using a 25U0.46 cm Supelcosil LC-18T
column, as previously described [15]. In some experiments, platelets
were lysed with 1/10 volume of 10% Triton X-100 before addition of
100 WM NGD. In other experiments, intact platelets were incubated
with NGD, and, at the end of the incubation time, 1/10 volume of
7 N perchloric acid was added, and samples were vigorously mixed
and placed on ice for 5 min. Samples were then centrifuged at
13 000Ug for 3 min and the acid extracts were neutralised and ex-
tracted with freon-trioctylamine as described [19]. Nucleotides were
then analysed by HPLC.
2.3. Measurement of Ca2 + release
Gel-¢ltered platelets were prepared at a ¢nal concentration of
2U109 cells/ml in HEPES bu¡er containing 10 Wg/ml leupeptin,
10 Wg/ml aprotinin, 2 U/ml creatine phosphokinase, 4 mM phosphoc-
reatine, 0.5 mM ATP, 1 mM MgCl2. Samples (0.4 ml) were pre-
warmed at 37‡C in a Perkin-Elmer spectro£uorimeter, and 6 WM
FLUO-3 was added. Platelets were then permeabilised by addition
of 50 Wg/ml saponin for 1 min. Ca2 release from intracellular stores
was stimulated by addition of 3 WM IP3 or 0.1^10 WM cADPR.
FLUO-3 £uorescence was continuously monitored at 490 nm excita-
tion and 535 nm emission.
3. Results and discussion
We investigated the e¡ect of platelet stimulation with the
strong agonists thrombin, collagen and the thromboxane A2
analogue U46619 on the ADP-ribosyl cyclase activity of
membrane CD38. All the agonists analysed caused an inhib-
ition of the synthesis of cGDPR from NGD by intact
platelets, which was reduced by 42 þ 20%, 19 þ 12%, and
25 þ 10% in thrombin-, collagen-, and U46619-treated plate-
lets, respectively (Fig. 1). Since the strongest e¡ect was ob-
served in thrombin-stimulated platelets we focused our in-
vestigations on this agonist. As thrombin is also a
proteolytic enzyme, we considered that the inhibitory e¡ect
on the ADP-ribosyl cyclase activity could be due to direct
proteolysis of the CD38 molecule, rather than to platelet
activation. However, Fig. 1 also shows that TRAP was as
e¡ective as thrombin in inhibiting the ADP-ribosyl cyclase
activity of CD38 (44 þ 2% inhibition), demonstrating that
this e¡ect was mediated by signals generated through the ac-
tivation of the thrombin receptor. Moreover, we never ob-
served release of ADP-ribosyl cyclase activity in the super-
natant of thrombin-stimulated platelets, indicating that this
enzyme did not induce membrane CD38 shedding (data not
shown).
We have previously shown that thrombin induces the asso-
ciation of about 40% of the platelet ADP-ribosyl cyclase ac-
tivity with the cytoskeleton [16]. Since this value was very
similar to the reduction of the ADP-ribosyl cyclase activity
measured in stimulated intact platelets, we considered that the
interaction of CD38 with the cytoskeleton could mediate the
inhibitory e¡ect of this agonist. Therefore, we analysed the
e¡ect of cytochalasin D, which prevents CD38 translocation
to the cytoskeleton without a¡ecting platelet aggregation
[16,20], on the synthesis of cGDPR by resting and throm-
bin-activated platelets. We found that in thrombin-stimulated
platelets, the inhibition of the ADP-ribosyl cyclase activity of
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Fig. 1. E¡ect of platelet stimulation on the ADP-ribosyl cyclase ac-
tivity of CD38. Gel-¢ltered platelets were treated with bu¡er (basal),
10 nM thrombin, 10 WM thrombin receptor activating peptide
(TRAP), 10 Wg/ml collagen, or 10 WM U46619 for 2 min. In some
experiments, gel-¢ltered platelets were preincubated with 10 WM cy-
tochalsin D (cytD) for 2 min before treatment with bu¡er (basal) or
10 nM thrombin. The ADP-ribosyl cyclase activity of CD38 was
then measured by incubation of the samples with 100 WM NGD
for 60 min, and the production of cGDPR was analysed by HPLC,
as described in Section 2. Results are the means þ S.D. of three to
eight di¡erent experiments. ***P6 0.001; **0.0016P6 0.01;
*0.026P6 0.05; n.s., not signi¢cant.
Table 1
ADP-ribosyl cyclase activity of CD38 in intact and lysed platelets
Resting platelets Thrombin-stimulated platelets
Intact platelets 37.8 þ 2.9 28.5 þ 2.3
Perchloric acid-lysed platelets 39.5 þ 1.0 28.6 þ 1.2
Triton X-100-lysed platelets 35.5 þ 2.5 27.8 þ 1.6
Gel-¢ltered platelets were treated with either bu¡er (resting platelets) or 10 nM thrombin (thrombin-stimulated platelets) for 2 min at 37‡C.
Samples of intact platelets were then incubated with 100 WM NGD for 60 min, and then platelets were pelleted by centrifugation and the
supernatants processed for HPLC analysis. NGD (100 WM) was also directly added to some other samples, but at the end of the incubation time,
platelets were lysed with perchloric acid, and the extracts were processed for HPLC analysis. In contrast, some samples were lysed with Triton X-
100 (1% ¢nal concentration) before addition of 100 WM NGD. Production of cGDPR by each sample was determined by HPLC analysis. Results
are expressed as pmol/min of cGDPR produced by 108 platelets, and represent the means þ S.D. of three to ¢ve experiments.
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CD38 was completely prevented by treatment of the cells with
cytochalasin D (Fig. 1). Therefore we conclude that the re-
duced production of cGDPR in thrombin-stimulated platelets
is a consequence of the agonist-induced interaction of CD38
with the intracellular cytoskeleton. In this regard, it is inter-
esting to note that collagen and U46619, which were reported
to be less potent than thrombin in promoting the interaction
of CD38 with the actin ¢laments [16], also caused a reduced
inhibition of the ADP-ribosyl cyclase activity in intact plate-
lets (Fig. 1).
We considered that the reduced accumulation of cGDPR
observed in thrombin-stimulated intact platelets could re£ect
not a real inhibition of the ADP-ribosyl cyclase activity of
CD38, but other events, including, for instance, a stimulated
in£ux of the synthesised cGDPR into the platelet, or increased
binding to the membrane, as well as the internalisation of
CD38 upon binding to the actin ¢laments. To verify these
possibilities, we measured the production of cGDPR in rest-
ing and thrombin-stimulated platelets using di¡erent ap-
proaches. In one set of experiments, intact resting and throm-
bin-stimulated platelets were incubated with NGD, and the
total nucleotides, including extracellular, intracellular, and
membrane bound pools, were extracted by addition of
perchloric acid and analysed by HPLC. Table 1 shows that
even when the total cell nucleotides were considered, a re-
duced amount of cGDPR was present in samples of throm-
bin-treated platelets compared to resting cells. To verify
whether our results could re£ect a reduced accessibility of
CD38 to the extracellular substrate in thrombin-stimulated
platelets, resting and thrombin-aggregated cells were lysed
with 1% Triton X-100 before addition of the NGD. Treat-
ment with Triton X-100 preserves the interaction of CD38
with the actin ¢laments, but solubilises the cell membrane
and allows NGD to reach potentially internalised active sites
of CD38 molecules. Table 1 shows that even when NGD was
added after cell membrane disruption, the amount of cGDPR
measured in thrombin-stimulated platelets was reduced com-
pared to resting cells. Therefore, we conclude that the reduc-
tion of cGDPR observed in thrombin-activated intact plate-
lets was not due to internalisation of CD38 or in£ux of
cGDPR, but to the inhibition of the ADP-ribosyl cyclase
activity of the enzyme. Recently, Higashida et al. reported
that the inhibition of membrane associated ADP-ribosyl cy-
clase activity is promoted by activation of m2 and m4 mus-
carinic acetylcholine receptors by a mechanism involving a
pertussis toxin-sensitive G-protein [14]. Our data are in agree-
ment with this report, since the thrombin receptor, which
mediates the inhibition of the ADP-ribosyl cyclase activity
in intact platelets, is known to be associated to the pertussis
toxin-sensitive G-protein Gi [21]. Therefore, our results pro-
vide further evidence that the enzymatic activity of CD38 can
be modulated by signals generated through G-protein-coupled
receptors.
It is known that thrombin stimulation of platelets induces a
rapid rise in the intracellular Ca2 concentration [17]. If the
function of CD38 in platelets was related to the control of
Ca2 movements, one would expect an increase of the ADP-
ribosyl cyclase activity upon cell activation rather than an
inhibition. However, the presence of cADPR-sensitive Ca2
stores in platelets has not so far been demonstrated. There-
fore, we investigated whether cADPR was able to promote the
release of Ca2 from internal stores in these cells. Gel-¢ltered
platelets were permeabilised with saponin in the presence of
FLUO-3, and then cADPR or IP3 were added. Fig. 2 shows
that while IP3 caused a signi¢cant release of Ca2, no re-
sponse to cADPR was observed. This nucleotide displayed
no e¡ects even when used at concentrations up to 10 WM
(data not shown). These results suggest that, unlike other
cells, platelets do not possess cADPR-sensitive Ca2 stores,
and, therefore, it is unlikely that this nucleotide plays a role in
Ca2 release in platelets.
This evidence raises the question of the physiological func-
tion of CD38 in platelets. Recently it has been reported that in
addition to NAD, CD38 can also use NADP as a substrate
to produce a di¡erent compound through a base exchange
reaction involving nicotinic acid, nicotine acid adenine dinu-
cleotide phosphate (NAADP), which displays Ca2-mobilising
activity by acting on intracellular stores distinct from those
sensitive to either IP3 or cADPR [22,23]. The metabolism of
NADP by platelet CD38 and the possible role of NAADP as
a Ca2-mobilising agent in these cells deserve further inves-
tigation. We may, however, hypothesise that the thrombin-
induced inhibition of the ADP-ribosyl cyclase activity de-
scribed in this work may represent a way to switch the enzy-
matic activity of CD38 to the base exchange reaction to in-
crease the production of NAADP. It is also possible that
platelet CD38 may play a role unrelated to Ca2 mobilisation.
It is known that the synthesised cADPR is rapidly hydrolysed
to ADPR by the same CD38 molecule [6]. Previous studies
have demonstrated that ADPR is an inhibitor of platelet ac-
tivation induced by several agonists [24]. Therefore, it is pos-
sible that CD38 contributes to a tonic negative control of
platelet function and that the inhibition of the ADP-ribosyl
cyclase activity induced by thrombin may represent a way to
remove, at least in part, this inhibitory e¡ect.
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Fig. 2. Ca2 release induced by IP3 and cADPR. Gel-¢ltered plate-
lets were permeabilised with 50 Wg/ml saponin in the presence of the
£uorescent Ca2 probe FLUO-3. Release of Ca2 from internal
stores was stimulated by the addition of 3 WM IP3 or 100 nM
cADPR. Typical £uorescent traces, representative of at least three
di¡erent experiments, are reported.
M. Torti et al./FEBS Letters 431 (1998) 19^22 21
References
[1] Metha, K., Shahid, U. and Malavasi, F. (1996) FASEB J. 12,
1408^1417.
[2] Dianzani, U., Funaro, A., Di Franco, D., Garbarino, G., Bra-
gardo, M., Redoglia, V., Buon¢glio, D., De Monte, L.B., Pileri,
A. and Malavasi, F. (1994) J. Immunol. 153, 952^957.
[3] Nishina, H., Inageda, K., Takahashi, K., Hoshino, S., Ikeda, K.
and Katada, T. (1994) Biochem. Biophys. Res. Commun. 203,
1318^1323.
[4] Funaro, A., Spagnoli, G.C., Ausiello, C.M., Alessio, M., Rog-
gero, S., Delia, D., Zaccolo, M. and Malavasi, F. (1990) J. Im-
munol. 145, 2390^2396.
[5] Santos-Argumedo, L., Teixeira, C., Preace, G., Kirkham, P.A.
and Parkhouse, R.M.E. (1993) J. Immunol. 151, 3119^3130.
[6] Howard, M., Grimaldi, J.C., Bazan, J.F., Lund, F.E., Santos-
Argumedo, L., Parkhouse, R.M.E., Walseth, T.F. and Lee,
H.C. (1993) Science 262, 1026^1029.
[7] Galione, A. (1993) Science 259, 325^326.
[8] Kontani, K., Nishina, H., Ohoka, Y., Takahashi, K. and Kata-
da, T. (1993) J. Biol. Chem. 268, 16895^16898.
[9] Grimaldi, J.C., Balasubramanian, S., Kabra, N.H., Shanafelt, A.,
Bazan, J.F., Zurawski, G. and Howard, M.C. (1995) J. Immunol.
155, 811^817.
[10] Zocchi, E., Franco, L., Guida, L., Calder, L. and De Flora, A.
(1995) FEBS Lett. 359, 35^40.
[11] Umar, S., Malavasi, F. and Metha, K. (1996) J. Biol. Chem. 271,
15922^15927.
[12] Galione, A., White, A., Willmott, N., Turner, M., Potter, B.V.L.
and Watson, S.P. (1993) Nature 365, 456^459.
[13] Willmott, N., Sethi, J.K., Walseth, T.F., Lee, H.C., White, A.M.
and Galione, A. (1996) J. Biol. Chem. 271, 3699^3705.
[14] Higashida, H., Yokoyama, S., Hashii, M., Taketo, M., Higashi-
da, M., Takayasu, T., Ohshima, T., Takasawa, S., Okamoto, H.
and Noda, M. (1998) J. Biol. Chem. 272, 1272^31277.
[15] Ramaschi, G., Torti, M., Tolnai Festetics, E., Sinigaglia, F.,
Malavasi, F. and Balduini, C. (1996) Blood 87, 2308^2313.
[16] Torti, M., Tolnai Festetics, E., Bertoni, A., Sinigaglia, F. and
Balduini, C. (1998) FEBS Lett. (in press).
[17] Heemskerk, J.W.M. and Sage, S.O. (1994) Platelets 5, 295^316.
[18] Grae¡, R.M., Walseth, T.F., Fryxell, K., Dale Branton, W. and
Lee, H.C. (1994) J. Biol. Chem. 269, 30260^30267.
[19] Hammer, D.F., Underferth, D.V., Kelley, R.E., Harvan, P.A.
and Altschuld, R.A. (1988) Anal. Biochem. 169, 300^305.
[20] Torti, M., Tolnai Festetics, E., Bertoni, A., Sinigaglia, F. and
Balduini, C. (1996) Thromb. Haemost. 76, 444^449.
[21] Brass, L.F., Manning, D.R., Cichowski, K. and Abrams, C.S.
(1997) Thromb. Haemost. 78, 581^589.
[22] Lee, H.C. and Aarhus, R. (1995) J. Biol. Chem. 270, 2152^2157.
[23] Aarhus, R., Grae¡, R.M., Dickey, D.M., Walseth, T.F. and Lee,
H.C. (1995) J. Biol. Chem. 270, 30327^30333.
[24] Del Principe, D., Menichelli, A., Casini, A., Di Giulio, S., Man-
cuso, G. and Finazzi-AgroØ, A. (1986) FEBS Lett. 205, 66^70.
FEBS 20475 13-7-98
M. Torti et al./FEBS Letters 431 (1998) 19^2222
